216 related articles for article (PubMed ID: 12022908)
21. Low-molecular-weight heparins in conjunction with thrombolysis for ST-elevation acute myocardial infarction. A critical review of the literature.
Rubboli A; Ottani F; Capecchi A; Brancaleoni R; Galvani M; Swahn E
Cardiology; 2007; 107(2):132-9. PubMed ID: 16864962
[TBL] [Abstract][Full Text] [Related]
22. Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy.
Prescrire Int; 2005 Aug; 14(78):127-32. PubMed ID: 16106594
[TBL] [Abstract][Full Text] [Related]
23. Anticoagulation monitoring part 2: Unfractionated heparin and low-molecular-weight heparin.
Spinler SA; Wittkowsky AK; Nutescu EA; Smythe MA
Ann Pharmacother; 2005; 39(7-8):1275-85. PubMed ID: 15956240
[TBL] [Abstract][Full Text] [Related]
24. Therapy of unstable angina with the low molecular weight heparins.
Ageno W; Turpie AG
Vasc Med; 2000; 5(4):217-23. PubMed ID: 11213233
[TBL] [Abstract][Full Text] [Related]
25. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
26. Current roles and future possibilities for low-molecular-weight heparins in unstable angina.
Purcell H; Fox KM
Eur Heart J; 1998 Sep; 19 Suppl K():K18-23. PubMed ID: 9790285
[TBL] [Abstract][Full Text] [Related]
27. Generic low-molecular-weight heparins: some practical considerations.
Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
[TBL] [Abstract][Full Text] [Related]
28. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
[TBL] [Abstract][Full Text] [Related]
29. An equivalence study of two low-molecular-weight heparins in the prevention and treatment of deep-vein thrombosis after total hip replacement.
Planès A
Semin Thromb Hemost; 2000; 26 Suppl 1():57-60. PubMed ID: 11011808
[TBL] [Abstract][Full Text] [Related]
30. Recent clinical trials in the treatment of venous thromboembolism and unstable angina with low molecular weight heparins.
Hirsh J
Curr Opin Hematol; 1998 Sep; 5(5):360-5. PubMed ID: 9776217
[TBL] [Abstract][Full Text] [Related]
31. Enoxaparin and dalteparin in unstable angina: new indication. Enoxaparin: a reference treatment. Dalteparin: no better than unfractionated heparin.
Prescrire Int; 1999 Jun; 8(41):77-80. PubMed ID: 10558446
[TBL] [Abstract][Full Text] [Related]
32. A systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiency.
Atiq F; van den Bemt PM; Leebeek FW; van Gelder T; Versmissen J
Eur J Clin Pharmacol; 2015 Aug; 71(8):921-9. PubMed ID: 26071276
[TBL] [Abstract][Full Text] [Related]
33. A critical review of clinical trials for low-molecular-weight heparin therapy in unstable coronary artery disease.
Husted S; Becker R; Kher A
Clin Cardiol; 2001 Jul; 24(7):492-9. PubMed ID: 11444639
[TBL] [Abstract][Full Text] [Related]
34. The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes.
Haas S
Semin Vasc Med; 2003 May; 3(2):139-46. PubMed ID: 15199477
[TBL] [Abstract][Full Text] [Related]
35. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety.
Hirsh J; Warkentin TE; Shaughnessy SG; Anand SS; Halperin JL; Raschke R; Granger C; Ohman EM; Dalen JE
Chest; 2001 Jan; 119(1 Suppl):64S-94S. PubMed ID: 11157643
[No Abstract] [Full Text] [Related]
36. Low molecular weight heparins for venous thromboembolism.
Drug Ther Bull; 1998 Apr; 36(4):25-9. PubMed ID: 9684414
[TBL] [Abstract][Full Text] [Related]
37. Comparative pharmacokinetics of LMWHs.
Samama MM; Gerotziafas GT
Semin Thromb Hemost; 2000; 26 Suppl 1():31-8. PubMed ID: 11011804
[TBL] [Abstract][Full Text] [Related]
38. Low-molecular-weight heparins: are they interchangeable?
van der Heijden JF; Prins MH; Büller HR
Haemostasis; 2000; 30 Suppl 2():148-57; discussion 146-7. PubMed ID: 11251361
[TBL] [Abstract][Full Text] [Related]
39. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
[TBL] [Abstract][Full Text] [Related]
40. Dosing low molecular weight heparins in kidney disease.
Saltiel M
J Pharm Pract; 2010 Jun; 23(3):205-9. PubMed ID: 21507815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
